Evenity Access in 2026: What Providers and Prescribers Need to Know

Evenity (romosozumab-aqqg) is one of the most powerful tools available for treating severe postmenopausal osteoporosis — but getting it into patients' hands requires navigating a complex specialty medication access pathway. This briefing covers the current access landscape, clinical eligibility, prior authorization strategies, specialty pharmacy coordination, and patient support resources relevant to prescribers in 2026.

Current Availability Status: Not an Official Shortage

As of 2026, Evenity is not listed on either the FDA Drug Shortage Database or the ASHP shortage list. Amgen continues manufacturing without reported supply disruptions. Patient access challenges are structural — driven by payer controls and specialty distribution — not manufacturing limitations.

FDA-Approved Indication and Clinical Eligibility

Evenity is FDA-approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as:

A history of osteoporotic fracture, OR

Multiple risk factors for fracture, OR

Patients who have failed or are intolerant to other available osteoporosis therapy

The AACE and Endocrine Society guidelines position anabolic therapy (including romosozumab) as first-line treatment for patients at very high fracture risk — those with a T-score ≤ -3.0, multiple prior fractures, or fractures on antiresorptive therapy. The ARCH trial demonstrated that Evenity followed by alendronate reduced vertebral fracture risk by 48% and hip fracture risk by 38% compared to alendronate alone.

Boxed Warning: Cardiovascular Risk — Clinical Screening Is Essential

Evenity carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. Key prescribing considerations:

Do not initiate Evenity in patients who have had an MI or stroke within the preceding 12 months.

Conduct an individualized benefit-risk assessment for patients with other cardiovascular risk factors.

Discontinue Evenity if the patient experiences an MI or stroke during therapy.

Counsel patients to seek immediate care for symptoms of MI or stroke (chest pain, sudden numbness, vision changes, etc.).

Additional Monitoring Requirements

Hypocalcemia: Correct pre-existing hypocalcemia before initiating therapy. Monitor calcium levels, particularly in patients with severe renal impairment or on dialysis.

Osteonecrosis of the jaw (ONJ): Perform a dental exam before initiating therapy. Risk is elevated by concurrent use of bisphosphonates, denosumab, chemotherapy, corticosteroids, or angiogenesis inhibitors.

Atypical femoral fractures: Evaluate any patient reporting thigh/groin pain during therapy.

Calcium and vitamin D supplementation: All patients should receive adequate calcium and vitamin D supplementation throughout the 12-month course.

Navigating Prior Authorization in 2026

Prior authorization is required by virtually all insurers for Evenity. To maximize first-pass approval rates, include the following in your PA submission:

DXA scan results with T-scores at lumbar spine, total hip, and femoral neck

Documentation of prior fragility fractures (type, date, mechanism)

Prior osteoporosis treatment history (drug, dose, duration, reason for discontinuation)

10-year fracture probability (FRAX score) if available

Cardiovascular history (confirming no MI or stroke in preceding 12 months)

According to Amgen's data, 87% of patients at very high fracture risk have no step therapy or a single-step edit access to Evenity through medical benefit coverage. However, payer requirements vary significantly — always check the specific plan formulary.

Specialty Pharmacy and Distribution Coordination

Evenity is typically billed under the medical benefit (not pharmacy benefit) as a buy-and-bill medication in many physician office settings, or sourced through specialty pharmacy and shipped to the site of care. Key considerations:

Evenity J-code is J3111 for medical benefit billing.

Medicare Part B covers Evenity administered in a physician office (80% after deductible).

Specialty pharmacies (Accredo, CVS Specialty, Walgreens Specialty) ship cold-chain to the site of care. Establish a relationship with one to streamline monthly ordering.

Amgen SupportPlus: Essential Resource for Prescribers

Amgen SupportPlus (1-844-AMGEN-11) provides your practice with benefits verification, prior authorization assistance, specialty pharmacy coordination, and patient copay support. Enrolling patients through SupportPlus — particularly at the time of prescribing — significantly reduces delays and administrative burden for your staff.

Sequencing After Evenity: Critical Transition Planning

The anabolic effect of Evenity wanes after 12 monthly doses — transition to an antiresorptive agent is mandatory to preserve gains. Clinical guidelines (AACE) recommend following Evenity with bisphosphonates (alendronate, zoledronic acid) or denosumab. Failure to transition leads to rapid bone density loss. Plan the transition therapy before initiating Evenity so the patient seamlessly continues treatment.

Tools for Your Practice

For patients who face pharmacy access difficulties despite having insurance coverage and an approved PA, medfinder for Providers can help locate specialty pharmacies in your patient's area that can source and coordinate Evenity delivery.